Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Ten Years of Pathology on Twitter (X): Landscape and Evolution of Pathology on Twitter From 2012 to 2023
Tian, Roland, Wang, Eric , Sivasubramaniam, Priyadharshini , Baskota, Swikrity Upadhyay , Sharma, Anurag , Cecchini, Matthew J.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 10, 2024 | Volume: 149 | Issue: 1 | Pages: 75-82

10.5858/arpa.2023-0447-oa | PMID 38599590 Get It

Context.— Social media is a powerful tool in pathology education and professional networking that connects pathologists and pathology trainees from around the world. Twitter (X) appears to be the most popular social media platform pathologists use to share pathology-related content and connect with other pathologists. Although there has been some published research on pathology-related activity on Twitter during short time frames, to date there has not been published research examining pathology-related Twitter activity in totality from its earliest days of activity to recently. Objective.— To comprehensively evaluate the use of pathology on Twitter (X) during the last 10 years. Design.— Pathology-related tweets were systematically scraped from Twitter from January 2012 to January 2023 using pathology hashtags as a surrogate measure for all pathology content on Twitter. COVID-related tweets were approximated by tweets containing the term “COVID.” Results.— There were 591 812 unique pathology-related tweets identified during the time period, with #pathology being the most common hashtag used and #PathTwitter becoming more popular since 2020. There has been positive annual growth of pathology Twitter, with peaks in use during major pathology conferences. During the initial phases of the COVID-19 pandemic, a sustained increase in pathology tweets was observed. Conclusions.— Pathology Twitter has grown during the last 10 years and has become increasingly popular for pathology education and networking. With the changing landscape of social media platforms, this study provides an understanding of how pathology medical education and professional networking uses of social media happen and evolve over time.
Feeling Unwell: AJR Podcast Series on Wellness, Episode 1
Wang, Sherry S.

Mayo Clinic

American Journal of Roentgenology | April 10, 2024 | Volume: 222 | Issue: 5 | Pages: No page available

10.2214/ajr.24.31267 | PMID 38598356 Get It

Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study
Crane, Genevieve M. , Geyer, Julia T. , Wang, Sa A. , Li, Ke David, Davis, Adam R. , Bosler, David , Bueso‐Ramos, Carlos E. , Bagg, Adam , Hasserjian, Robert P. , Hsi, Eric D , Thakral, Beenu , Wool, Geoffrey D. , Boiocchi, Leonardo , Arber, Daniel A. , George, Tracy I. , Orazi, Attilio , Hsi, Eric D. , Rogers, Heesun J.

Mayo Clinic

American Journal of Clinical Pathology | April 10, 2024 | Volume: 162 | Issue: 3 | Pages: 233-242

10.1093/ajcp/aqae033 | PMID 38597584 Get It

Abstract Objectives Myeloproliferative neoplasm, unclassifiable (MPN-U, revised to MPN, not otherwise specified in the fifth edition of the World Health Organization classification) is a heterogeneous category of primary marrow disorders with clinical, morphologic, and/or molecular features that preclude classification as a more specific MPN subtype due to stage at diagnosis, overlapping features between MPN subtypes, or the presence of coexisting disorders. Compared with other MPN subtypes, the contribution of the mutational landscape in MPN-U in conjunction with other clinical and morphologic biomarkers to prognosis has been less well investigated. Methods We performed a multicenter, retrospective study of MPN-U (94 cases) to better define the clinicopathologic features, genetic landscape, and clinical outcomes, including subgroups of early-stage, advanced-stage, and coexisting disorders. The Dynamic International Prognostic Scoring System (DIPSS) plus scoring system was applied to assess its relevance to MPN-U prognosis. Results Multivariate analysis demonstrated bone marrow blast count and DIPSS plus score as statistically significant in predicting overall survival. Univariate analysis identified additional potential poor prognostic markers, including abnormal karyotype and absence of JAK2 mutation. Secondary mutations were frequent in the subset analyzed by next-generation sequencing (26/37 cases, 70.3%) with a borderline association between high molecular risk mutations and overall survival. Conclusions This study, as one of the largest of MPN-U studies incorporating both clinicopathologic and molecular data, moves toward identification of biomarkers that better predict prognosis in this heterogeneous category.
Retinal Color Fundus Photography and Deep Learning can Discriminate Alzheimer’s Disease (P8-9.006)
Dumitrașcu, Oana , Li, Xin , Sobczak, Jacob, Zhu, Wenhui , Caselli, Richard J. , Woodruff, Bryan K. , Wang, Yalin

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204695 Get It

Half-and-Half Syndrome as Manifestation of Acute Ischemic Stroke (P8-10.005)
Zakhia, George, Wang, Han

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204796 Get It

Unusual Cause of Facial Rash - Traumatic Scalp Arteriovenous Fistula (AVF) (P7-5.011)
Zakhia, George, Wang, Han

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204794 Get It

Accelerated Endothelial Dysfunction in Migraine with Aura Compared to Migraine Without Aura in Patients of Different Age and Sex Groups Identified by an Artificial Intelligence-ECG Age-estimation Algorithm (P5-12.001)
Wang, Han , Lim, Elisabeth S. , Zhang, Nan , Baez‐Suarez, Abraham, Friedman, Paul A. , Cutrer, Michael, Tietjen, Gretchen E. , Attia, Zachi I. , Noseworthy, Peter A. , Chao, Chieh‐Ju , Chhabra, Nikita , Cutrer, Michael, Schwedt, Todd J. , Dodick, David W. , Chiang, Chia‐Chun

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204586 Get It

Serum Levels of NLRP3 Inflammasome Signaling Protein ASC - A Prognostic Tool in Pediatric Traumatic Brain Injury (P9-8.007)
Bernal, Julia, Swaby, Kathryn, Snodgrass, Kourtney, Coto, Jennifer , Gober, Joslyn , Pareja, Jennifer Munoz, Chavez, Maria Mateo , de Rivero Vaccari, Juan Pablo , Pringle, Charlene , Solano, Juan, Wang, Kevin , Keane, Robert W. , Dietrich, W. Dalton , Pareja, Jennifer C. Muñoz

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204350 Get It

Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri, Ahmad , Lester, Steven J., Stendahl, John C. , Hegde, Sheila M. , Sehnert, Amy J. , Balaratnam, Ganesh, Fox, Shawna, Wang, Andrew , Wang, Andrew , Sehnert, Amy J , Hegde, Sheila M , Shah, Ashish

Mayo Clinic

Journal of the American Heart Association | April 9, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.030607 | PMID 38591260 Get It

Background The phase 2 PIONEER‐HCM (Phase 2 Open‐label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) study showed that mavacamten improved left ventricular outflow tract gradients, exercise capacity, and symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM), but the results of longer‐term treatment are less well described. We report interim results from the PIONEER‐OLE (PIONEER Open‐Label Extension) study, the longest‐term study of mavacamten in patients with symptomatic obstructive HCM. Methods and Results Patients who previously completed PIONEER‐HCM (n=20) were eligible to enroll in PIONEER‐OLE. Patients received oral mavacamten, 5 mg once daily (starting dose), with individualized dose titration at week 6. Evaluations included serial monitoring of safety, echocardiography, Kansas City Cardiomyopathy Questionnaire–Overall Summary Score, and serum NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels. Thirteen patients enrolled and received mavacamten (median study duration at data cutoff, 201 weeks). Most patients (92.3%) received β‐blockers concomitantly. Treatment‐emergent adverse events were predominantly mild/moderate. One patient had an isolated reduction in left ventricular ejection fraction to 47%, which recovered and remained normal with continued treatment at a reduced dose. At week 180, mavacamten was associated with New York Heart Association class improvements from baseline (class II to I, n=9; class III to II, n=1; and unchanged, n=2), sustained reductions in left ventricular outflow tract gradients (mean [SD] change from baseline: resting, −50 [55] mm Hg; Valsalva, −70 [41] mm Hg), and serum NT‐proBNP levels (median [interquartile range] change from baseline: −498 [−2184 to −76] ng/L), and improved Kansas City Cardiomyopathy Questionnaire–Overall Summary Score (mean [SD] change from baseline: +17 [16]). Conclusions This long‐term analysis supports the continued safety and effectiveness of mavacamten for >3 years in obstructive HCM. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03496168.
The Clinical Impact of the 4Kscore Test on Prostate Biopsy Decision Making in the Setting of MRI
Wang, Johnny , Vetter, Joel , Gross, James T. , Henning, Grant , Henning, Grant M , Kim, Eric H.

Mayo Clinic

JU Open Plus | April 8, 2024 | Volume: 2 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000134 Get It

Introduction: Biomarkers are often used in conjunction with MRI to improve the specificity of prostate cancer screening. Our objective was to evaluate the real-world utility of the 4Kscore test in the setting of MRI. We explored the association of the 4Kscore test with the decision to pursue prostate biopsy and its contribution to the accurate detection of clinically significant prostate cancer. Methods: We retrospectively analyzed patients undergoing the 4Kscore test and MRI for consideration of prostate biopsy. Multivariable logistic regression was used to model the association of 4Kscore with the decision to pursue biopsy. Receiver-operating characteristic curves were used to calculate the AUC of 4Kscore alone, PSA with MRI, and 4Kscore with MRI for detection of Gleason Grade Group ≥ 2 (GG ≥ 2) prostate cancer. Results: Of 442 patients, 311 (70%) proceeded to biopsy. 4Kscore was associated with the decision to pursue biopsy for continuous (odds ratio [OR] 1.05 per 1-point increase in 4Kscore, 95% confidence interval [CI] 1.02-1.07; P < .001) and categorical (high-risk 4Kscore: OR 16.1, 6.62-39.3, P < .001; intermediate-risk 4Kscore: OR 6.89, 95% CI 3.15-15.1; P < .01) models. For the detection of GG ≥ 2 prostate cancer, the AUC of 4Kscore with MRI (AUC = 0.866) was superior to 4Kscore alone (AUC = 0.800, P < .001) and PSA with MRI (AUC = 0.792, P < .001). Conclusions: In patients with MRI, the 4Kscore is associated with the decision to pursue prostate biopsy and augments the accurate prediction of GG ≥ 2 prostate cancer. Our findings suggest 4Kscore provides independent information as an adjunct to MRI for real-world clinical decision making.